(DOX) Amdocs - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: GB0022569080
Stock:
Total Rating 44
Risk 92
Buy Signal -1.05
| Risk 5d forecast | |
|---|---|
| Volatility | 24.8% |
| Relative Tail Risk | -1.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.05 |
| Alpha | -32.01 |
| Character TTM | |
|---|---|
| Beta | 0.529 |
| Beta Downside | 0.390 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.95% |
| CAGR/Max DD | -0.28 |
EPS (Earnings per Share)
Revenue
Description: DOX Amdocs
Amdocs Limited, through its subsidiaries, provides software and services to communications, entertainment, media, and other service providers worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud offering. The company also provides CES25, a telco-native, GenAI-led customer experience suite, spanning business, and operations and network domains that is embedded with AI and related tools. In addition, it offers GenAI agents, and which include Customer Engagement Platform, a telecom-specific customer relationship management (CRM) solution; Amdocs Monetization Suite which enables customers to monetize their broad set of services and offerings; Amdocs Intelligent Networking Suite, a set of solutions that provide end-to-end service orchestration; Amdocs Charging; Amdocs eSIM Cloud that enables service providers to offer digital SIM (eSIM); Amdocs MarketONE, a based Software-as-a-Service (SaaS)-based platform that includes pre-integrated digital services, ranging from media, gaming, eLearning, sports and retail to security, and business services; and Amdocs connectX, a cloud-native telco-in-a-box software-as-a-service platform for digital telecom brands, as well as Amdocs CatalogONE that spans the entire CES25 suite and combines embedded business intelligence with telecom-specific GenAI agents. Further, the company provides consulting, experience design, data, cloud, network services, delivery, quality engineering, operations, systems integration, and content services to various platforms and technologies; maintenance, enhancement design and development, and operational support services; network deployment and optimization services; and managed services, including AI and related tools, predictive analytics, and robotic process automation, as well as quality engineering, mobile network, cloud, and professional services. Amdocs Limited was founded in 1982 and is headquartered in Saint Louis, Missouri.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 571.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 3.03 > 1.0 |
| NWC/Revenue: 1.81% < 20% (prev 4.56%; Δ -2.74% < -1%) |
| CFO/TA 0.14 > 3% & CFO 863.7m > Net Income 571.9m |
| Net Debt (704.5m) to EBITDA (950.6m): 0.74 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (108.5m) vs 12m ago -4.34% < -2% |
| Gross Margin: 37.60% > 18% (prev 0.36%; Δ 3724 % > 0.5%) |
| Asset Turnover: 72.46% > 50% (prev 77.38%; Δ -4.91% > 0%) |
| Interest Coverage Ratio: 17.35 > 6 (EBITDA TTM 950.6m / Interest Expense TTM 43.3m) |
Altman Z'' 5.81
| A: 0.01 (Total Current Assets 1.54b - Total Current Liabilities 1.46b) / Total Assets 6.34b |
| B: 1.13 (Retained Earnings 7.16b / Total Assets 6.34b) |
| C: 0.12 (EBIT TTM 750.8m / Avg Total Assets 6.32b) |
| D: 1.19 (Book Value of Equity 3.42b / Total Liabilities 2.88b) |
| Altman-Z'' Score: 5.81 = AAA |
Beneish M -3.12
| DSRI: 1.03 (Receivables 962.8m/990.9m, Revenue 4.58b/4.87b) |
| GMI: 0.96 (GM 37.60% / 35.95%) |
| AQI: 1.01 (AQ_t 0.61 / AQ_t-1 0.60) |
| SGI: 0.94 (Revenue 4.58b / 4.87b) |
| TATA: -0.05 (NI 571.9m - CFO 863.7m) / TA 6.34b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of DOX shares?
As of February 25, 2026, the stock is trading at USD 67.26 with a total of 1,181,799 shares traded.
Over the past week, the price has changed by -1.70%, over one month by -19.38%, over three months by -10.18% and over the past year by -21.94%.
Over the past week, the price has changed by -1.70%, over one month by -19.38%, over three months by -10.18% and over the past year by -21.94%.
Is DOX a buy, sell or hold?
Amdocs has received a consensus analysts rating of 4.71.
Therefore, it is recommended to buy DOX.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DOX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 93.8 | 39.5% |
| Analysts Target Price | 93.8 | 39.5% |
DOX Fundamental Data Overview February 21, 2026
P/E Trailing = 13.6367
P/E Forward = 10.9051
P/S = 1.6772
P/B = 2.2252
P/EG = 1.2116
Revenue TTM = 4.58b USD
EBIT TTM = 750.8m USD
EBITDA TTM = 950.6m USD
Long Term Debt = 647.1m USD (from longTermDebt, last quarter)
Short Term Debt = 167.8m USD (from shortTermDebt, last quarter)
Debt = 952.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 704.5m USD (from netDebt column, last quarter)
Enterprise Value = 8.38b USD (7.68b + Debt 952.4m - CCE 247.9m)
Interest Coverage Ratio = 17.35 (Ebit TTM 750.8m / Interest Expense TTM 43.3m)
EV/FCF = 11.11x (Enterprise Value 8.38b / FCF TTM 754.9m)
FCF Yield = 9.00% (FCF TTM 754.9m / Enterprise Value 8.38b)
FCF Margin = 16.49% (FCF TTM 754.9m / Revenue TTM 4.58b)
Net Margin = 12.49% (Net Income TTM 571.9m / Revenue TTM 4.58b)
Gross Margin = 37.60% ((Revenue TTM 4.58b - Cost of Revenue TTM 2.86b) / Revenue TTM)
Gross Margin QoQ = 37.04% (prev 37.38%)
Tobins Q-Ratio = 1.32 (Enterprise Value 8.38b / Total Assets 6.34b)
Interest Expense / Debt = 1.18% (Interest Expense 11.3m / Debt 952.4m)
Taxrate = 18.91% (37.0m / 195.4m)
NOPAT = 608.8m (EBIT 750.8m * (1 - 18.91%))
Current Ratio = 1.06 (Total Current Assets 1.54b / Total Current Liabilities 1.46b)
Debt / Equity = 0.28 (Debt 952.4m / totalStockholderEquity, last quarter 3.42b)
Debt / EBITDA = 0.74 (Net Debt 704.5m / EBITDA 950.6m)
Debt / FCF = 0.93 (Net Debt 704.5m / FCF TTM 754.9m)
Total Stockholder Equity = 3.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.05% (Net Income 571.9m / Total Assets 6.34b)
RoE = 16.56% (Net Income TTM 571.9m / Total Stockholder Equity 3.45b)
RoCE = 18.31% (EBIT 750.8m / Capital Employed (Equity 3.45b + L.T.Debt 647.1m))
RoIC = 14.73% (NOPAT 608.8m / Invested Capital 4.13b)
WACC = 7.10% (E(7.68b)/V(8.63b) * Re(7.86%) + D(952.4m)/V(8.63b) * Rd(1.18%) * (1-Tc(0.19)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.04%
[DCF] Terminal Value 82.29% ; FCFF base≈676.3m ; Y1≈720.2m ; Y5≈864.5m
[DCF] Fair Price = 162.7 (EV 18.27b - Net Debt 704.5m = Equity 17.57b / Shares 107.9m; r=7.10% [WACC]; 5y FCF grow 7.21% → 2.90% )
EPS Correlation: 83.28 | EPS CAGR: 4.40% | SUE: 2.26 | # QB: 1
Revenue Correlation: -19.24 | Revenue CAGR: 0.25% | SUE: 0.40 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.76 | Chg7d=-0.040 | Chg30d=-0.040 | Revisions Net=-3 | Analysts=4
EPS current Year (2026-09-30): EPS=7.46 | Chg7d=+0.002 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+6.7% | Growth Revenue=+3.5%
EPS next Year (2027-09-30): EPS=8.12 | Chg7d=+0.025 | Chg30d=+0.053 | Revisions Net=+3 | Growth EPS=+8.9% | Growth Revenue=+3.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.6% (Discount Rate 7.9% - Earnings Yield 7.3%)
[Growth] Growth Spread = +2.7% (Analyst 3.4% - Implied 0.6%)
P/E Forward = 10.9051
P/S = 1.6772
P/B = 2.2252
P/EG = 1.2116
Revenue TTM = 4.58b USD
EBIT TTM = 750.8m USD
EBITDA TTM = 950.6m USD
Long Term Debt = 647.1m USD (from longTermDebt, last quarter)
Short Term Debt = 167.8m USD (from shortTermDebt, last quarter)
Debt = 952.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 704.5m USD (from netDebt column, last quarter)
Enterprise Value = 8.38b USD (7.68b + Debt 952.4m - CCE 247.9m)
Interest Coverage Ratio = 17.35 (Ebit TTM 750.8m / Interest Expense TTM 43.3m)
EV/FCF = 11.11x (Enterprise Value 8.38b / FCF TTM 754.9m)
FCF Yield = 9.00% (FCF TTM 754.9m / Enterprise Value 8.38b)
FCF Margin = 16.49% (FCF TTM 754.9m / Revenue TTM 4.58b)
Net Margin = 12.49% (Net Income TTM 571.9m / Revenue TTM 4.58b)
Gross Margin = 37.60% ((Revenue TTM 4.58b - Cost of Revenue TTM 2.86b) / Revenue TTM)
Gross Margin QoQ = 37.04% (prev 37.38%)
Tobins Q-Ratio = 1.32 (Enterprise Value 8.38b / Total Assets 6.34b)
Interest Expense / Debt = 1.18% (Interest Expense 11.3m / Debt 952.4m)
Taxrate = 18.91% (37.0m / 195.4m)
NOPAT = 608.8m (EBIT 750.8m * (1 - 18.91%))
Current Ratio = 1.06 (Total Current Assets 1.54b / Total Current Liabilities 1.46b)
Debt / Equity = 0.28 (Debt 952.4m / totalStockholderEquity, last quarter 3.42b)
Debt / EBITDA = 0.74 (Net Debt 704.5m / EBITDA 950.6m)
Debt / FCF = 0.93 (Net Debt 704.5m / FCF TTM 754.9m)
Total Stockholder Equity = 3.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.05% (Net Income 571.9m / Total Assets 6.34b)
RoE = 16.56% (Net Income TTM 571.9m / Total Stockholder Equity 3.45b)
RoCE = 18.31% (EBIT 750.8m / Capital Employed (Equity 3.45b + L.T.Debt 647.1m))
RoIC = 14.73% (NOPAT 608.8m / Invested Capital 4.13b)
WACC = 7.10% (E(7.68b)/V(8.63b) * Re(7.86%) + D(952.4m)/V(8.63b) * Rd(1.18%) * (1-Tc(0.19)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.04%
[DCF] Terminal Value 82.29% ; FCFF base≈676.3m ; Y1≈720.2m ; Y5≈864.5m
[DCF] Fair Price = 162.7 (EV 18.27b - Net Debt 704.5m = Equity 17.57b / Shares 107.9m; r=7.10% [WACC]; 5y FCF grow 7.21% → 2.90% )
EPS Correlation: 83.28 | EPS CAGR: 4.40% | SUE: 2.26 | # QB: 1
Revenue Correlation: -19.24 | Revenue CAGR: 0.25% | SUE: 0.40 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.76 | Chg7d=-0.040 | Chg30d=-0.040 | Revisions Net=-3 | Analysts=4
EPS current Year (2026-09-30): EPS=7.46 | Chg7d=+0.002 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+6.7% | Growth Revenue=+3.5%
EPS next Year (2027-09-30): EPS=8.12 | Chg7d=+0.025 | Chg30d=+0.053 | Revisions Net=+3 | Growth EPS=+8.9% | Growth Revenue=+3.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 0.6% (Discount Rate 7.9% - Earnings Yield 7.3%)
[Growth] Growth Spread = +2.7% (Analyst 3.4% - Implied 0.6%)